Pamidronate for pain in adult chronic nonbacterial osteitis (PAM-CNO): protocol of a randomized, double-blind, placebo-controlled trial

Abstract

Abstract Chronic nonbacterial osteitis (CNO) is a rare auto-inflammatory bone disease affecting children and adults. Adult CNO is characterized by painful bone lesions, primarily of the anterior chest wall. There is no approved therapy for adult CNO. Current off-label treatments include intravenous bisphosphonates, which have been shown to alleviate pain through decreasing bone turnover. However, no adequately powered randomized controlled trials (RCTs) have been conducted. This double-blind, placebo-controlled RCT investigates the efficacy of intravenous pamidronate to decrease bone pain in adult CNO patients. Recruiting at the Dutch national referral center for CNO, adult patients with persistent bone pain despite non-steroidal anti-inflammatory drugs, or optionally other standard-of-care treatments are randomized to receive two courses of intravenous pamidronate (at 0 and 3 months, 30 mg daily, on 3 consecutive days) or placebo. From 6 months onwards, all patients receive open-label pamidronate for another two courses. The primary outcome is change in score for maximum pain from 0-6 months. Secondary outcomes include change in quantitative intralesional bone turnover as measured on sodium-fluoride positron emission computed tomography ([18F]NaF-PET/CT), inflammation markers, shoulder function, general health, quality of life, fatigue, physical and work activity. The PAM-CNO trial addresses the need for evidence-based treatments in adult CNO. Results will directly impact daily clinical practice, either validating the use of intravenous pamidronate in CNO at the dose used in this trial, or prompting the search for alternative regimens or agents. This trial was registered in EudraCT (reference 2020-001068-27), and the Dutch Trial Register (reference NL68020.058.20).